Biocartis announced the completion of an EUR 30 million Series E equity fundraising. The additional capital will be used to validate Biocartis’ molecular diagnostics platform IdyllaTM and its first assay and to continue the development of a range of assays, primarily in the oncology field.
This series E round was entirely subscribed by the existing shareholders such as RMM (Rudi Mariën), Debiopharm Diagnostics SA, PMV Tina Fund, Valiance, Johnson & Johnson Development Corporation, Philips, the Wellcome Trust, Petercam, the family offices of Dr. Paul Janssen, Luc Verelst, Rudi Pauwels (founder of Biocartis) and some smaller shareholders, including some employees.